Twice-Yearly PrEP Is Here: What You Need to Know About the New HIV Prevention Shot
Living with HIV means committing to a daily routine. For millions of people around the world, that routine includes taking antiretroviral therapy (ART) every single day — without exception. One missed dose can mean a drop in viral suppression. Two missed doses can lead to resistance. The pressure is constant. The pills are always there. And over time, that weight becomes exhausting. It's called pill fatigue — and it's one of the most common challenges people living with HIV face.But what if there was another way? What if you could maintain complete viral suppression without a daily pill?In recent years, long-acting injectable HIV treatments have emerged as a game-changing alternative. These are not experimental therapies — they are FDA-approved, clinically proven, and available today. Instead of taking a pill every morning, you receive a single injection every one to two months. That's it. No daily reminder. No pharmacy trips every few weeks. No fear of missing a dose.
HIV prevention has taken a meaningful step forward with the approval of a long-acting injectable option that only requires two doses per year. For many people, remembering a daily pill is a real barrier to consistent protection. This new approach addresses that challenge directly, offering a more manageable schedule without sacrificing effectiveness.
This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.
What Is the New PrEP Injection in 2026?
The new PrEP injection approved for use is known by the brand name Yeztugo, developed by Gilead Sciences. It contains lenacapavir, a capsid inhibitor that works differently from older antiretroviral medications. Rather than requiring daily dosing, Yeztugo is administered just twice a year, making it one of the most infrequent dosing schedules of any HIV prevention medication currently available. The FDA approval of Yeztugo marked a notable shift in the long-acting PrEP landscape, adding a second injectable option alongside the existing cabotegravir injection, which requires dosing every two months.
How Does Long-Acting PrEP Work?
Understanding how long-acting PrEP works helps clarify why this approach is considered effective. Lenacapavir targets the HIV capsid protein, which plays a critical role in the virus replication cycle. By disrupting this process, the drug prevents HIV from establishing infection in the body. Because lenacapavir has a long half-life, it can remain active in the body at protective levels for approximately six months after each injection. This pharmacological profile is what makes the twice-yearly schedule scientifically feasible, rather than simply a convenience feature.
The Yeztugo FDA Approval and Clinical Evidence
The FDA approval of Yeztugo was supported by results from the PURPOSE 2 clinical trial, which evaluated lenacapavir in a broad population including cisgender men, transgender women, transgender men, and gender nonbinary individuals who have sex with partners assigned male at birth. The trial results showed that lenacapavir reduced HIV infections by approximately 96 percent compared to background incidence rates, and demonstrated superiority over daily oral PrEP with emtricitabine and tenofovir disoproxil fumarate in certain participant groups. These findings provided strong evidence for the drug’s effectiveness across diverse populations.
Who Is the Twice-Yearly HIV Prevention Shot For?
The twice-yearly HIV prevention shot is intended for adults and adolescents weighing at least 35 kilograms who are at risk of acquiring HIV and do not currently have the virus. It is particularly relevant for individuals who find daily oral medication challenging to maintain consistently, whether due to lifestyle factors, privacy concerns, or personal preference. Healthcare providers will assess individual health profiles, potential drug interactions, and other factors before recommending Yeztugo. As with any medication, it is not suitable for everyone, and a thorough consultation with a qualified provider is an essential first step.
Access, Cost, and Insurance Considerations
Access to newer HIV prevention medications in the United States often depends on insurance coverage, income level, and available assistance programs. Long-acting injectable PrEP options generally carry higher list prices than generic daily oral PrEP pills, though manufacturer patient assistance programs and federal initiatives like the Ready, Set, PrEP program can significantly reduce out-of-pocket costs for eligible individuals.
| Product/Service | Provider | Cost Estimation |
|---|---|---|
| Yeztugo (lenacapavir injection, twice yearly) | Gilead Sciences | List price not yet widely published; patient assistance available |
| Apretude (cabotegravir injection, every 2 months) | ViiV Healthcare | Approx. $3,700–$4,200 per injection before assistance |
| Daily oral PrEP – Truvada generic | Various generic manufacturers | Approx. $30–$60/month with insurance or assistance |
| Daily oral PrEP – Descovy | Gilead Sciences | Approx. $1,800–$2,000/month list price; covered by many plans |
Prices, rates, or cost estimates mentioned in this article are based on the latest available information but may change over time. Independent research is advised before making financial decisions.
Where Can You Get the New PrEP Injection?
Yeztugo will be administered in clinical settings, as it is an injectable medication rather than a self-administered pill. Community health centers, sexual health clinics, primary care providers, and infectious disease specialists are likely points of access. Organizations such as Planned Parenthood, federally qualified health centers, and HIV service organizations in your area may also offer or facilitate access to long-acting PrEP. Telehealth platforms that specialize in sexual health are increasingly helping patients navigate prescriptions and referrals for injectable PrEP options as well.
The arrival of a twice-yearly HIV prevention shot represents a genuine expansion of options for people seeking protection against HIV in the United States. With strong clinical trial data supporting its effectiveness and a dosing schedule that reduces the burden of daily adherence, this new injectable form of PrEP has the potential to reach populations that have historically faced barriers to consistent prevention. As access continues to develop and insurance frameworks adapt, staying informed and consulting with a healthcare provider remains the most practical path forward for anyone considering this option.
